TY - JOUR
T1 - Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia
T2 - a discrete choice experiment
AU - Ashaye, Ajibade
AU - Thomas, Caitlin
AU - Dalal, Mehul
AU - Kota, Vamsi
AU - Krucien, Nicolas
AU - Sae-Hau, Maria
AU - Weiss, Elisa
AU - Campbell, Scott
AU - Marsh, Kevin
N1 - Funding Information:
This study was funded by Takeda Development Center Americas Inc. A Ashaye, M Dalal and S Campbell are employees of and own stock options in Takeda Development Center Americas Inc. C Thomas, N Krucien, and K Marsh are employees of Evidera, which was paid by Takeda Development Center Americas Inc. to conduct this study. V Kota is employed by the Section of Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA and was paid by Takeda Development Center Americas Inc. for work related to this study. M Sae-Hau and E Weiss are employees of the Leukemia & Lymphoma Society, Rye Brook, NY, USA. The Leukemia & Lymphoma Society received funding from Evidera, who conducted the study sponsored by Takeda Development Center Americas Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing was provided by J Pitt (Evidera, Paris, France) and funded by Takeda Development Center Americas Inc.
Publisher Copyright:
© 2022 Takeda Development Center Americas, Inc.
PY - 2022/6
Y1 - 2022/6
N2 - Aim: We examined the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for benefits and risks of tyrosine kinase inhibitors combined with chemotherapy for first-line treatment. Methods: In a discrete choice experiment, 201 patients chose between hypothetical treatment alternatives with varied levels of remission duration and overall survival (OS), and risks of major cardiovascular (CV) events and myelosuppression. Results: Although OS was the most important attribute to patients with Ph+ ALL, they were willing to tolerate a 2.9% increase in CV risk for 1 additional month of OS. Older patients (>59 years) and patients not in remission were less likely to tolerate increased CV risk. Conclusion: Preferences and risk tolerance varied between patients, highlighting the importance of shared decision making when selecting treatments for Ph+ ALL. Plain language summary Treatments differ in their potential benefits and side effects they may come with. Patients should be involved in deciding which treatments they receive. This is because patients may have different views than physicians on how the benefits and side effects of treatment would affect their quality of life. Additionally, patients may have different risk tolerances. This study shows how patients with a form of leukemia valued survival benefits and side effects of treatments, and the trade-offs that they were willing to make between these. On average, longer survival had most value to patients. They were willing to accept a higher risk of a major cardiovascular side effect (e.g., having a stroke) if the treatment would allow them to live longer. However, not all patients had the same opinion, and some groups of patients were less willing to accept risks to receive longer survival. By involving patients in treatment decisions, we can help ensure they receive treatments that match their personal preferences.
AB - Aim: We examined the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for benefits and risks of tyrosine kinase inhibitors combined with chemotherapy for first-line treatment. Methods: In a discrete choice experiment, 201 patients chose between hypothetical treatment alternatives with varied levels of remission duration and overall survival (OS), and risks of major cardiovascular (CV) events and myelosuppression. Results: Although OS was the most important attribute to patients with Ph+ ALL, they were willing to tolerate a 2.9% increase in CV risk for 1 additional month of OS. Older patients (>59 years) and patients not in remission were less likely to tolerate increased CV risk. Conclusion: Preferences and risk tolerance varied between patients, highlighting the importance of shared decision making when selecting treatments for Ph+ ALL. Plain language summary Treatments differ in their potential benefits and side effects they may come with. Patients should be involved in deciding which treatments they receive. This is because patients may have different views than physicians on how the benefits and side effects of treatment would affect their quality of life. Additionally, patients may have different risk tolerances. This study shows how patients with a form of leukemia valued survival benefits and side effects of treatments, and the trade-offs that they were willing to make between these. On average, longer survival had most value to patients. They were willing to accept a higher risk of a major cardiovascular side effect (e.g., having a stroke) if the treatment would allow them to live longer. However, not all patients had the same opinion, and some groups of patients were less willing to accept risks to receive longer survival. By involving patients in treatment decisions, we can help ensure they receive treatments that match their personal preferences.
KW - Philadelphia chromosome
KW - acute lymphoblastic leukemia
KW - discrete choice experiment
KW - hematologic neoplasms
KW - patient preference
KW - shared decision making
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85129734558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129734558&partnerID=8YFLogxK
U2 - 10.2217/fon-2022-0082
DO - 10.2217/fon-2022-0082
M3 - Article
C2 - 35209721
AN - SCOPUS:85129734558
SN - 1479-6694
VL - 18
SP - 2075
EP - 2085
JO - Future Oncology
JF - Future Oncology
IS - 17
ER -